Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Pharmacoepidemiology and Drug Safety
|
April 3, 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
Andrew J P Cooper, Sally Lettis, Charlotte L Chapman, et al.
Journal of Medicinal Chemistry
|
December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
J E Cobb, S G Blanchard, E G Boswell, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 26, 1999
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
J L Oberfield, J L Collins, C P Holmes, et al.
Journal of Medicinal Chemistry
|
June 8, 2000
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures
D R Bolin, A L Swain, R Sarabu, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Pharmacoepidemiology and Drug Safety
|
April 3, 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
Andrew J P Cooper, Sally Lettis, Charlotte L Chapman, et al.
Journal of Medicinal Chemistry
|
December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent
J E Cobb, S G Blanchard, E G Boswell, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 26, 1999
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
J L Oberfield, J L Collins, C P Holmes, et al.
Journal of Medicinal Chemistry
|
June 8, 2000
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures
D R Bolin, A L Swain, R Sarabu, et al.
Page
of 5